logo
Twitter
Discord
Email
logo
Senseonics Holdings, Inc.

Senseonics Holdings, Inc.

AMEX•SENS
CEO: Dr. Timothy T. Goodnow Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2015-12-22
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Contact Information
20451 Seneca Meadows Parkway, Germantown, MD, 20876-7005, United States
301-515-7260
www.senseonics.com
Market Cap
$254.09M
P/E (TTM)
-4.3
4
Dividend Yield
--
52W High
$28.00
52W Low
$5.25
52W Range
4%
Rank59Top 76.7%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$8.10M+89.89%
4-Quarter Trend

EPS

-$0.43-44.30%
4-Quarter Trend

FCF

-$15.98M+9.37%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Nine Months Total revenue increased $6.83M to $21.00M for nine months ended September 2025, driven by consignment growth.
Gross Profit Turnaround Gross profit improved $11.51M to $8.09M profit for nine months ended September 2025, benefiting from prior year charges.
Equity Position Swing Stockholders' equity swung $94.72M to $78.17M positive balance as of September 30, 2025, reversing deficit.
Financing Provided Cash $77.09M cash provided by financing activities for nine months 2025, largely from recent Public Offering proceeds.

Risk Factors

Going Concern Substantial Doubt Substantial doubt exists regarding ability to continue as going concern past twelve months without additional liquidity.
Ascensia Transition Uncertainty Commercial transition from Ascensia starting 2026 involves uncertain final terms, costs, and liabilities negotiation.
Liquidity Needs Critical Requires additional capital funding over next twelve months to sustain operations and expanded commercialization efforts.
Limited Commercial Experience Limited commercial stage history facing difficulties in competitive, rapidly evolving medical device markets.

Outlook

Resume US Commercial Control Plan to resume US commercial responsibility from Ascensia starting January 1, 2026, pending definitive agreement.
New Product Development Focus Advancing Gemini product development; seeking IDE submission by end of 2025 based on 365-day sensor data.
Sequel Collaboration Integration Integrating Sequel Med Tech technologies to create first automated insulin delivery system by Q4 2025.
Evaluate Funding Strategies Evaluating strategies to obtain required additional funding through public or private debt and equity financings.

Peer Comparison

Revenue (TTM)

Owens & Minor, Inc.OMI
$6.71B
-37.1%
The Oncology Institute, Inc.TOI
$461.04M
+21.7%
Treace Medical Concepts, Inc.TMCI
$218.88M
+7.9%

Gross Margin (Latest Quarter)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
Treace Medical Concepts, Inc.TMCI
79.1%
-1.1pp
NeuroPace, Inc.NPCE
77.4%
+4.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SRDX$614.51M-34.8-15.6%19.2%
NPCE$524.21M-25.5-116.7%66.4%
RXST$506.15M-15.6-11.6%3.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.8%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 2, 2026
|
EPS:-$0.43
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $8.10M+89.9%
    |
    EPS: $-0.43-44.3%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $8.30M+70.5%
    |
    EPS: $-0.52-21.0%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $6.26M+24.0%
    |
    EPS: $-0.40-35.5%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|
    Revenue: $22.47M+0.4%
    |
    EPS: $-2.50-13.6%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $4.26M-30.1%
    |
    EPS: $-0.77-5.2%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $4.87M+17.9%
    |
    EPS: $-0.66-8.6%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $5.05M+22.0%
    |
    EPS: $-0.61-1237.0%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 1, 2024|
    Revenue: $22.39M+36.6%
    |
    EPS: $-2.20-136.7%
    Miss